Brief: US FDA sent warning letter to Bausch & Lomb on September 4
15/09/2026 15:34
BRIEF-US FDA sent warning letter to Bausch & Lomb on September 4 Sept 15 (Reuters) - US FDA:
US FDA: SENT WARNING LETTER TO BAUSCH & LOMB INC ON SEPT 4 - WEBSITE
US FDA: WARNING LETTER TO BAUSCH & LOMB FOR SIGNIFICANT CURRENT GOOD MANUFACTURING PRACTICE VIOLATIONS AT TAMPA DRUG MANUFACTURING FACILITY
Further company coverage: BLCO.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser